Ataibeckley Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated September 8, 2026, covers the results of a virtual special meeting of stockholders held by Ataibeckley Inc. (ATAI) on that date. The meeting was convened to vote on proposals related to a proposed merger with Eli Lilly and Company (Lilly) via its wholly owned subsidiary, Albali Acquisition Corporation.
Key Financial Metrics
The filing does not provide specific financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity for the reporting period. The document focuses exclusively on corporate governance and the status of the merger transaction.
Material Changes and Voting Results
At the special meeting, stockholders approved two key proposals:
- Proposal 1 (Merger Proposal): Approved the Agreement and Plan of Merger with Eli Lilly and Company.
- Votes For: 237,762,253
- Votes Against: 5,033,755
- Abstentions: 555,549
- Proposal 2 (Adjournment Proposal): Approved the ability to adjourn the meeting to solicit additional proxies if necessary.
- Votes For: 229,411,340
- Votes Against: 12,814,164
- Abstentions: 1,126,053
As the Merger Proposal was approved, the Adjournment Proposal was not acted upon. A total of 243,351,557 shares (approximately 65.6% of outstanding shares) were present or represented by proxy, establishing a quorum.
Outlook, Management Commentary, and Risks
Assuming the satisfaction or waiver of all remaining conditions, Ataibeckley expects the merger to be consummated on September 11, 2026. The filing includes extensive forward-looking statements regarding the transaction. Key risks and contingencies identified include:
- Failure to obtain required regulatory clearances.
- Failure to satisfy or waive conditions to closing.
- Potential delays or termination of the Merger Agreement.
- Disruption to ongoing business operations and management attention.
- Uncertainty regarding the payment of contingent value rights (milestone payments).
- Integration risks for Lilly and the continued development of Ataibeckley's programs.
- Global macroeconomic conditions and trade disputes.
Investor Verification Checklist
- Verify the definitive proxy statement filed on August 10, 2026, for detailed terms of the Merger Agreement.
- Confirm the status of regulatory clearances required for the merger with Eli Lilly.
- Monitor the expected closing date of September 11, 2026, for any delays or changes.
- Review the specific terms of contingent value rights and milestone payments outlined in the Merger Agreement.
- Check for any legal proceedings instituted against the parties that could impact the transaction.